Loading company…
Sagimet Biosciences develops therapeutics for cancer and infectious diseases.
Sagimet Biosciences is a clinical-stage pharmaceutical company developing therapeutics for oncology and infectious diseases, including NASH. Its programs include TVB-2640, which targets fatty acid synthase, and antivirals for RSV, CMV, and other pathogens. Founded in 2006 by Lucas Pelkmans and Urs Greber, the company is based in San Mateo, US. In February 2021, it raised USD 80 million from Altium Capital, Kleiner Perkins, and New Enterprise Associates.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in